Latanoprost: Two year's experience of its use in the United Kingdom

Ophthalmology

Volumn 105, Issue 1, 1998, Pages 82-87

  Watson, Peter G ^a  

^a NONE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LATANOPROST; TIMOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; EYE DROPS; PROSTAGLANDIN F;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EYE COLOR; FEMALE; FOLLOW UP; HUMAN; HYPERPIGMENTATION; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TOPICAL DRUG ADMINISTRATION; UNITED KINGDOM; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DRUG EFFECT; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PIGMENT DISORDER; SAFETY;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; DOUBLE-BLIND METHOD; EYE COLOR; FEMALE; GLAUCOMA, OPEN-ANGLE; GREAT BRITAIN; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; PIGMENTATION DISORDERS; PROSTAGLANDINS F, SYNTHETIC; SAFETY; TIMOLOL;

EID: 0031600299     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-6420(98)91372-0     Document Type: Article

References (17)

1. Alm A, Villumsen J. PhXA34, a new potent ocular hypotensive drug. A study on dose-response relationship and on aqueous humor dynamics in healthy volunteers. Arch Ophthalmol 1991;109:1564-8.
2. 2α-isopropyl ester analogues for glaucoma treatment. Jpn J Ophthalmol 1993;7:259-69.
3. α analogue, after topical application in normal and ocular hypertensive human eyes. Arch Ophthalmol 1993; 111:1351-8.
4. Aim A, Villumsen J, Törnquist P, et al. Intraocular pressure-reducing effect of PhXA41 in patients with increased eye pressure: a one-month study. Ophthalmology 1993; 100:1312-7.
5. 2α analog, on aqueous humor dynamics in human eyes. Ophthalmology 1993;100:1297-304.
6. Aim A, Widengard I, Kjellgren D, et al. Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol. Br J Ophthalmol 1995;79:12-6.
7. Camras CB. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma. Ophthalmology 1996;103:138-47.
8. Mishima HK, Masuda K, Kitazawa Y, et al. A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. Arch Ophthalmol 1996;114:929-32.
9. Watson P, Stjernschantz J. A six-month, randomized double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. Ophthalmology 1996;103:126-37.
10. 2α and its isopropylester on normal and glaucomatous human eyes. In: Bito LZ, Stjernschantz J, eds. The Ocular Effects of Prostaglandins and Other Eicosanoids. New York: Alan R Liss, 1989;447-58.
11. Aim A. The potential of prostaglandin derivatives in glaucoma therapy. Curr Opin Ophthalmol 1993;4:44-50.
12. Hotehama Y, Mishima HK, Kitazawa Y, Masuda K. Ocular hypotensive effect of PHXA41 in patients with ocular hypertension or primary open-angle glaucoma. Jpn J Ophthalmol 1993;37:270-4.
13. Nagasubramanian S, Sheth GP, Hitchings RA, Stjernschantz J. Intraocular pressure-reducing effect of PhXA41 in ocular hypertension: comparison of dose regimens. Ophthalmology 1993;100:1305-11.
14. 2α analogue (PhXA41). An inhospital, placebo-controlled study. Arch Ophthalmol 1993;111:657-61.
15. Aim A, Stjernschantz, J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Ophthalmology 1995;102:1743-52.
16. Imesch PD, Bindley CD, Khademian Z, et al. Melanocytes and iris color. Electron microscopic findings. Arch Ophthalmol 1996;114:443-7.
17. Wilkerson CL, Syed NA, Fisher MR, et al. Melanocytes and iris color. Light microscopic findings. Arch Ophthalmol 1996;114:437-42.